TREVI THERAPEUTICS INC
TRVI
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company whose primary drug candidate, oral nalbuphine ER, has been tested in animal models as part of its preclinical development. The company’s SEC filings acknowledge that its research activities are subject to the Animal Welfare Act. Cruelty Free Investors lists the company for animal testing related to its medical product development. This preclinical animal testing is a standard, required step in the pharmaceutical regulatory pathway for bringing a new drug to market.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.